Date: 2015-06-17
Type of information: R&D agreement
Compound:
Company: Anika Therapeutics (USA – MA) Institute for Applied Life Sciences at the University of Massachusetts (UMass) Amherst (US - MA)
Therapeutic area: Autoimmune diseases – Inflammatory diseases - Rheumatic diseases
Type agreement: R&D collaboration
Action mechanism:
Disease: rheumatoid arthritis
Details: * On June 17, 2015, Anika Therapeutics announced an agreement with the Institute for Applied Life Sciences at the University of Massachusetts (UMass) Amherst to collaborate on research to develop a therapy for rheumatoid arthritis. The purpose of this research collaboration is to develop a novel modality for the treatment of rheumatoid arthritis, and if successful, is expected to yield a candidate that will move toward clinical development in 2017. "This partnership combines Professor Sankaran Thayumanavan's (Chemistry) expertise in nanotechnology with Professor Lisa Minter's (Veterinary & Animal Sciences) mechanistic understanding of aberrant immune responses and with Anika's proven knowledge of hyaluronic acid chemistry and its clinical application to treat joint pain," said Professor Mike Malone , Vice Chancellor for Research and Engagement at UMass Amherst.
Financial terms:
Latest news:
